Chemotherapy for patients with recurrent or refractory neuroblastoma: A POG phase II study

American Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 1, 1997, Pages 62-67

  Alvarado, Carlos S ^a   Kretschmar, C ^b   Joshi, V V ^c   Toledano, S ^d   Cantor, A ^e   Strother, D ^f   Nitschke, R ^g   Castleberry, R P ^h  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e Pediat Oncol Grp Stat Office   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g OKLAHOMA CITY UNIVERSITY   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Carboplatin; High dose cisplatin; Ifosfamide; Recurrent neuroblastoma; Sodium thiosulfate

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; SODIUM THIOSULFATE;

ADOLESCENT; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER RESISTANCE; CATHETER INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; NEUROBLASTOMA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEUROBLASTOMA; RECURRENCE; TREATMENT OUTCOME;

EID: 0030960580     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199701000-00009     Document Type: Article

References (27)

1. Hayes FA, Green AA. Second complete remission (CR) in children with metastatic neuroblastoma. Proc Am Soc Clin Oncol 1985; 4: 237.
2. Castleberry RP, Green AA, Casper J, et al. A pilot of high dose cisplatinum (HDP) in children with recurrent neuroblastoma (NB). Proc Am Soc Clin Oncol 1987; 6: 218.
3. Philip T, Ghalie R, Pinkerton R, et al. A phase II study of high dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d’Oncologie Pediatrique. J Clin Oncol 1987; 5: 941-50.
4. Campbell LA, Seeger RC, Harris RE, et al. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol 1993; 11: 623-9.
5. Castello MA, Donfrancesco A, Clerico A, et al. High-dose carboplatin with etoposide (JET regimen) in children with advanced neuroblastoma. In: Evans AE, D’Angio GJ, Knudson AG, et al., eds. Advances in neuroblastoma, vol. 3. New York: Alan Liss, 1991: 535-42.
6. Frappaz D, Michon JN, Hartmann O, et al. Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol 1992; 10: 1592-601.
7. Ozols RF. Cisplatin dose intensity. Semin Oncol 1987; 16: 22-30.
8. Wong NLM, Mavichak V, Magil AB, et al. Sodium thiosulfate prevents cisplatin-induced hypomagnesemia. Nephron 1988; 50: 308-14.
9. Iannotti N, Markman M, D’Acquisita R, et al. Phase I trial of escalating doses of intravenous (IV) cisplatin (C) with IV sodium thiosulfate renal protection. Proc Am Soc Clin Oncol 1985; 55: 2072.
10. Pfeiffle CE, Howell SB, Felthouse RD, et al. High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 1985; 3: 237-44.
11. Filipski J, Kohn KW, Prather R, et al. Thiourea reverses crosslinks and restores biological activity in DNA treated with dichlorodiammine-platinum (II). Science 1979; 204: 181-3.
12. Shea M, Koziol JA, Howell SB. Kinetics of sodium thiosulfate, a cisplatin neutralizer. Clin Pharm Ther 1984; 35: 419-25.
13. Goren MP, Wright RK, Horowitz ME, et al. Cumulative tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1986; 18: 69-73.
14. Brock PR, Koliuskas DE, Barratt TM, et al. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 1991; 118: 531-4.
15. Womer RB, Pritchard J, Barratt TM. Renal toxicity of cisplatin in children. J Pediatr 1985; 106: 659-63.
16. Castleberry RP, Cantor AB, Green AA, et al. Phase II investigational window utilizing carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated, disseminated neuroblastoma: a Pediatric Oncology Group Study. J Clin Oncol 1994; 12: 1616-20.
17. Kellie SJ, De Kraker J, Lilleyman JS, et al. Ifosfamide in previously untreated disseminated neuroblastoma: results of study 3A of the European Neuroblastoma Study Group. Eur J Clin Oncol 1988; 24: 903-8.
18. Atassi G, Kennis Y, Dumont P, et al. Animal screening of new platinum derivatives. Studies with single agents and combinations [Abstract 27]. Fourth NCI-EORTC symposium on new drugs in cancer therapy, 1983.
19. Rozencweig M, Canetta R, Carter SK. Carboplatin: the clinical evaluation strategy. Cancer Treat Rev 1985; 12(suppl A): 137-44.
20. Ozols RF, Behrens BC, Ostchega Y, et al. High dose cisplatin and high dose carboplatin in refractory ovarian cancer patients. Cancer Treat Rev 1985; 12(suppl A): 59-65.
21. Bacha DM, Caparros-Sison B, Allen JA, et al. Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep 1986; 70: 865-9.
22. Brandt LJ, Broadberry V. Nephrotoxicity following carboplatin use in children: Is routine monitoring of renal function necessary? Med Ped Oncol 1993; 22: 31-5.
23. Reed E, Jacob J. Carboplatin and renal function [Letter]. Ann Intern Med 1989; 110: 409.
24. Le Chevalier T, Subirana R, Ruffie P, et al. Carboplatin-ifosfamide in untreated metastatic small cell lung carcinoma (SCLC). Proc Am Soc Clin Oncol 1989; 8: 237.
25. Eierman W, Meerpohl HG, Kuehnle H, et al. Phase II trial with carboplatin and ifosfamide in previously untreated patients with advanced squamous cell carcinoma of the cervix (SCCC). Proc Am Soc Clin Oncol 1989; 8: 159.
26. Gallagher CJ, Weltshaw E, Coleman RE, et al. A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer. Cancer Chemother Pharmacol 1989; 24: 54-7.
27. Goldin A. Ifosfamide in experimental tumor systems. Semin Oncol 1982; 9: 14-23.